It is a treatment for those people who are chronically infected with hepatitis C, including those suffering from cirrhosis or renal failure in any degree. The results of this treatment have been very satisfactory, since it has achieved high rates of effectiveness in seriously ill patients infected with chronic Hepatitis C.
Zepatier is an FDA approved drug and is not suitable for patients with moderate liver failure, only those in the chronic stage. This treatment lasts from 12 to 16 weeks depending on the critical situation in which the patient finds himself.
Zepatier is a direct action antiviral, it should be taken only one tablet per day and which has shown high cure rates in genotype 1 and genotype 4, including previously untreated patients with treatment experience with or without compensated cirrhosis. and those with chronic kidney disease.
It should be emphasized that chronic hepatitis C is a potentially devastating disease that can cause long-term health consequences for severely ill patients, including decreased liver function, liver failure, or liver cancer. Today, chronic hepatitis C is a curable disease for many patients, as there are multiple therapeutic tools that can mitigate its impact.
This treatment usually brings certain side effects, such as: fatigue, headache and nausea.
Doctors should perform liver lab tests on patients prior to therapy, treatment at week 8, and as clinically indicated. For patients who received 16 weeks of therapy, additional liver laboratory tests should be performed at week 12 of treatment. This is so that the results are more accurate and with a low margin of error.
